These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 34674551

  • 1. Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment.
    Romanelli F, Stolfa S, Morea A, Ronga L, Prete RD, Chironna M, Santacroce L, Mosca A.
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS, Baek JY, Ko J-H, Cho SY, Lee KY, Lee YH, Yang J, Kim TY, Huh HJ, Lee NY, Huh K, Kang C-I, Chung DR, Peck KR.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0034424. PubMed ID: 38687076
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
    Tsivkovski R, Lomovskaya O.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 32015028
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M, Li FH, Liu J, Li WJ, Yin RX, Cai DT, Andrey DO, Zheng SL, Gales AC, Zhang WJ, Sun J, Liao XP, Yu Y.
    J Antimicrob Chemother; 2024 May 02; 79(5):1069-1080. PubMed ID: 38526879
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae.
    Dulyayangkul P, Douglas EJA, Lastovka F, Avison MB.
    Antimicrob Agents Chemother; 2020 Sep 21; 64(10):. PubMed ID: 32660988
    [Abstract] [Full Text] [Related]

  • 15. In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae.
    Gaibani P, Ambretti S, Viale P, Re MC.
    J Antimicrob Chemother; 2019 May 01; 74(5):1457-1459. PubMed ID: 30649310
    [No Abstract] [Full Text] [Related]

  • 16. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P, Re MC, Campoli C, Viale PL, Ambretti S.
    Clin Microbiol Infect; 2020 Apr 01; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
    Antinori E, Unali I, Bertoncelli A, Mazzariol A.
    Clin Microbiol Infect; 2020 Jul 01; 26(7):946.e1-946.e3. PubMed ID: 32061796
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Lee YL, Ko WC, Hsueh PR.
    Int J Antimicrob Agents; 2022 Jul 01; 60(5-6):106679. PubMed ID: 36241011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.